Source: AllCare Physio/ Facebook
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Healthia (HLA) purchases two AllCare Physiotherapy stores and a John Holme Optometrist for $2.46 million
  • The company has also entered into an agreement to purchase Anytime Physio in Newstead, Queensland
  • The newly purchased business are expected to contribute a revenue of $3.95 million and EBITDA of $640,000
  • Managing Director, Wesley Coote, says the company’s vision is to build the leading allied health care business in the Australian market
  • On market close, Healthia was down 6.25 per cent, trading at $1.80 per share

Healthia (HLA) has agreed to purchase two AllCare Physiotherapy stores and a John Holme Optometrist for $2.46 million.

The physiotherapy clinics are located in Hobart, Tasmania, while the optometrist includes two stores in Northern Queensland.

The company has also entered into an agreement to purchase Anytime Physio in Newstead, Queensland.

The newly purchased businesses are expected to contribute a revenue of $3.95 million and earnings before interest, tax, depreciation and amortisation (EBITDA) of $640,000.

Managing Director, Wesley Coote, said the company’s vision is to build the leading allied health care business in the Australian market.

“Our key target sectors of Bodies and Minds, Feet and Ankles, and Eyes and Ears have a collective addressable market of $9.8 billion,” Mr Coote said.

“We have a proven management team and a clinician and patient first culture and are excited to have these businesses joining our growing allied health network.”

Since listing on the ASX in September 2018, Healthia has grown its portfolio of allied health businesses from 104 to 217. This marks a 109 per cent growth and the company will continue adding value to its portfolio of assets.

On market close, Healthia was down 6.25 per cent, trading at $1.80 per share.

HLA by the numbers
More From The Market Online

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…

Genetic Signatures wins TGA greenlight for flu test device – just before winter

Genetic Signatures (ASX:GSS) shares were down -1.45% to 68cps on Monday, even as the company reported…

PYC Therapeutics takes Polycystic Kidney Disease drug to human trials

PYC Therapeutics takes its latest drug for Polycystic Kidney Disease, characterized by the formation of cysts…